Emerging literature implicates abnormalities in gamma frequency oscillations in the pathophysiology of schizophrenia, with hypofunction of N-methyl-D-aspartate (NMDA) receptors implicated as a key factor. Prepulse inhibition (PPI) is a behavioural measure of sensorimotor gating, which is disrupted in schizophrenia. We studied relationships between ongoing and sensory-evoked gamma oscillations and PPI using pharmacological interventions designed to increase gamma oscillations (ketamine, MK-801); reduce gamma oscillations (LY379268); or disrupt PPI (amphetamine). We predicted that elevating ongoing gamma power would lead to increased 'neural noise' in cortical circuits, dampened sensory-evoked gamma responses and disrupted behaviour.
Introduction
Schizophrenia is a debilitating psychiatric condition characterized by deficits in many aspects of higher order behaviour, including information processing, sensory perception, and cognition (Elvevag and Goldberg, 2000) . The broad nature of the cognitive deficits has led to the conceptualization of schizophrenia as a disorder of neural networks (Spencer et al., 2003; Lewis et al., 2005; Uhlhaas and Singer, 2010) . In particular, high frequency (30-80 Hz; gamma) neuronal oscillations have received significant attention (Lee et al., 2003a; Uhlhaas and Singer, 2010; Gandal et al., 2012) due to a growing understanding of their important role in cognitive processes, which are disrupted in schizophrenia (Fell et al., 2001; Fries et al., 2001; Jensen et al., 2007) . Many reports document abnormal gamma activity in schizophrenia patients, with the findings largely falling into two distinct categories depending on the nature of the oscillations studied: (1) several reports describe reduced stimulusevoked gamma responses, suggesting an inappropriate sensory response to a given stimulus (e.g. (Kwon et al., 1999; Leicht et al., 2010) ; and (2) others report increases in ongoing, or baseline gamma frequency activity in schizophrenia patients (Baldeweg et al., 1998; Flynn et al., 2008; Spencer, 2011) , which might represent aberrant cortical network noise disrupting normal cognitive processing.
One prominent theory describing the underlying neurobiological mechanisms of schizophrenia revolves around N-methyl-D-aspartate receptor (NMDAr) hypofunction (Goff and Coyle, 2001; Coyle, 2012) . This theory was proposed based on observations that NMDAr antagonists, such as ketamine, induce symptoms in healthy volunteers reminiscent of those seen in schizophrenia, and exacerbate these symptoms in schizophrenia patients (Adler et al., 1998; Newcomer et al., 1999) . The molecular substrates mediating the neurophysiological deficits in schizophrenia are not fully understood, but NMDAr hypofunction presents a strong candidate mechanism. GABAergic parvalbumin (PV)-expressing inhibitory interneurons are believed to contribute to the generation of gamma frequency oscillations (Cobb et al., 1995) , and several lines of evidence suggest that NMDAr hypofunction can influence the activity of these interneurons and alter the regulation of gamma frequency oscillations. For example, ablation of NMDAr on PV interneurons increases ongoing gamma frequency spectral power (Korotkova et al., 2010; Carlen et al., 2012) . Administration of NMDAr antagonists dose-dependently increases ongoing cortical gamma oscillations in rodents (Pinault, 2008; Ehrlichman et al., 2009; Hakami et al., 2009; Jones et al., 2012; Kocsis, 2012; Kulikova et al., 2012) and reduces sensory-evoked gamma band responses (Kulikova et al., 2012; Saunders et al., 2012) , patterns which are akin to those commonly observed in patients with schizophrenia. However, there exists a substantial gap in our understanding of the causal connections between alterations in gamma oscillations induced by NMDAr antagonists and the behavioural and symptomatic consequences of these drugs. Specifically, does a state of NMDAr hypofunction cause any schizophrenia-like symptoms directly because of the effects on the regulation of gamma frequency oscillations? Further, the relationship between reductions in sensoryevoked gamma activity observed in schizophrenia and the symptom profile of these patients is similarly complex (Lee et al., 2003b) .
Sensorimotor gating deficits are prevalent endophenotypes of schizophrenia (Braff and Geyer, 1990) . While sensorimotor gating is not considered to be a cognitive measure per se, abnormalities in pre-attentive information processing may be predictive of, or lead to, complex cognitive deficits. Several studies have demonstrated that sensorimotor gating deficits are induced by administration of NMDAr antagonists, such as ketamine and MK-801, and also by other psychotomimetic compounds such as amphetamine (van den Buuse, 2010) , but the underlying neurophysiology regulating this behaviour has not been studied. Prepulse inhibition (PPI) is a widely used model of sensorimotor gating (Swerdlow et al., 2008) . It describes the behavioural observation that when a startling stimulus, such as a loud sound, is preceded by a non-startling stimulus, the response to the startle stimulus is reduced. We designed this study to investigate the relationships between gamma frequency oscillations -both ongoing and evoked -and the regulation of sensorimotor gating in the form of PPI of the acoustic startle response. To study sensory evoked gamma oscillations, we measured the electrophysiological response occurring immediately after the prepulse in the behavioural tests. This was based on the assumption that the prepulse is a defining element of the behaviour exhibited during a PPI session (see discussion in Yee and Feldon, 2009) , and allowed us to correlate electrophysiological changes with behavioural deficits. We hypothesized that drugs which elevate ongoing gamma power, such as NMDAr antagonists, would lead to a concurrent disruption of PPI, and, conversely, that drugs which reduce ongoing gamma power, such as the mGluR2/3 agonist LY379268 , would facilitate PPI. We also anticipated a strong relationship between the gamma frequency signal evoked by the prepulse and the regulation of PPI. Finally, we predicted that the strength of the evoked signal would be inversely related to background ongoing gamma activity.
Method

Animals
Adult male Wistar rats, aged 14-16 weeks at the time of surgery (n = 12; 250-350 g), were obtained from the Australian Resource Centre and housed at the Bio-Resources Facility of the Melbourne Brain Centre, Parkville, Australia. The facility was maintained on a 12 h light/dark cycle, lights on from 06:00-18:00, and food (standard rat chow) and water were available ad libitum. All procedures performed in this study were approved by the University of Melbourne Animal Ethics Committee (#1 011 868).
Surgical electrode implantation
At least one week following delivery of animals, surgical implantation of electrocorticogram (ECoG) recording electrodes was performed, as previously described (Jones et al., 2008) . Rats were anaesthetized by inhalation of isoflurane (5% induction, 1-2% maintenance) with equal parts of medical air and oxygen, and positioned in a stereotaxic frame. An incision was made along the midline of the scalp, and six holes were drilled through the skull without breaching the dura. Brass recording electrodes were gently screwed into the skull at 2 mm anterior and 2 mm lateral to bregma bilaterally (active electrodes); 2 mm posterior and 2 mm lateral to bregma bilaterally (reference electrodes); and 2 mm posterior and 2 mm lateral to lambda bilaterally (ground electrodes). The protruding ends of the electrodes were fitted to a plastic pedestal (PlasticsOne, Bioscientific Pty Ltd, Australia) and the pedestal was secured to the skull using dental cement.
Experimental design
This study consisted of simultaneous recording of ECoG and measurement of PPI. Prior to commencing the study, animals were handled several times and habituated to the equipment. At the start of each session, animals were connected to an ECoG cable (PlasticsOne, Bioscientific Pty Ltd, Australia) and placed in a 9 cm diameter Plexiglas cylinder inside an electrostatically shielded PPI startle chamber (SR-LAB, San Diego Instruments, USA). ECoG recording was initiated and, following a baseline EEG recording, the animal was taken from the chamber and injected s.c. with ketamine, MK-801, d-amphetamine, LY379268, or vehicle (0.9% saline), and then replaced within the chamber. The drug doses were chosen based on our previous work, which demonstrated that, in rats, 0.5 mg/kg ketamine and 0.16 mg/kg MK-801 both increase ongoing gamma activity (Hakami et al., 2009) , that 3.0 mg/kg LY379268 reduces ongoing gamma power , and that 0.5 mg/kg amphetamine disrupts PPI (Choy et al., 2009) . PPI sessions were initiated after injection and continued for the following 90 min, during which time the ECoG was recorded. Each animal received each drug on subsequent sessions in a pseudo-randomized, repeated measures design with a minimum of two rest days between sessions to allow drug 'wash-out'.
PPI measurement
A piezoelectric accelerometer unit attached underneath the platform of the Plexiglas cylinders detected the startle responses of the animals. Acoustic stimuli were delivered, and responses recorded, using SR-LAB startle software (San Diego Instruments). Sessions were programmed to include two trial types: 115 dB startle pulse-alone trials of 40 ms duration; and prepulse-pulse trials, in which the startle pulse was preceded by 100 ms (onset to onset) by a 78 dB prepulse of 20 ms duration (i.e., 8 dB above background which does not, by itself, cause a behavioural response). These two trial types were interspersed, and herein referred to as either pulse-alone trials or prepulse trials. Background noise was set at 70 dB. Average behavioural PPI was calculated in 5-min, 12 trial blocks which included six pulse-alone and six prepulse trials delivered in a pseudo-random order. The inter-trial interval varied randomly (15, 20, 25 or 40 s). After 30 min, PPI blocks were separated with 5 min of background noise. Percentage prepulse inhibition (%PPI) was calculated for each PPI block, with the formula 100×[(startle from pulsealone trials−startle from prepulse trials)/startle from pulse-alone trials)].
ECoG recording
The experiment used standard EEG equipment including a MacLab amplifier and A-D converter (ADInstruments, Australia), and Chart V4.5 Software (ADInstruments, Australia). ECoG was recorded continuously (sampling rate 1 kHz) on three channels for the duration of the session, one channel for each hemisphere (left and right), and the third channel was connected to the PPI amplifier to record the acoustic pulses. Noise emanating from the power mains (50 Hz) was controlled using selective eliminators (Humbugs; Digitimer, UK).
Analysing gamma oscillations
Ongoing gamma frequency data was analysed using NEUROSCAN ® software (Compumedics, Australia), and evoked electrophysiological responses were analysed using MATLAB software (v7.10.0, Natick, Massachusetts: The MathWorks Inc., 2010). For measurement of ongoing gamma power, initially the recording was notch filtered (49-51 Hz) and divided into 5 min blocks consisting of 2.05 s epochs (148 epochs per block). Every epoch was inspected visually for signal distortion or movement artifact -this process also removed all EEG epochs which contained the startling pulses. Using fast Fourier transformations (FFT), average power in the gamma frequency band (30-80 Hz) was determined for each 2.05 s epoch over the entire recording, and average power was calculated for each 5 min block (Hakami et al., 2009 ). This process was repeated for all animals in all conditions. The data were collated using custom-designed scripts written for MATLAB software. For the purpose of this study, the left and right hemisphere measures were averaged together. The first 5 min of habituation and the ∼5 min during injection were excluded from final analyses. The remaining values in the pre-injection period were averaged together to generate a baseline value for each individual recording, obtained while the animals were sitting quietly in the startle chamber. All subsequent values were expressed as a percentage of baseline [(raw power/baseline) × 100]. For measurement of stimulus-evoked gamma power, individual epochs covering 600 ms centred around the prepulse were isolated, and the baseline-corrected spectral power, or event-related spectral perturbation (ERSP), calculated using the EEGLAB toolbox (Delorme and Makeig, 2004) . ERSP was calculated from 20 to 120 Hz, with morlet wavelets ranging from three cycles at lower frequencies to ten at the highest. Baseline gamma power (mean power 30-80 Hz, −400 to −150 ms relative to onset of the prepulse), prepulse gamma power (0 to +60 ms relative to onset of prepulse) and pulse gamma power (+100 to +160 ms relative to prepulse, which is 0 to +60 ms relative to the pulse) was then extracted for each individual trial and averaged into 5 min blocks for correlation with PPI data.
Drugs
Isoflurane was obtained from Abbott Australasia Pty Ltd, Australia and carprofen (Rimadyl), obtained from Pfizer Animal Health Group, UK, was administered as post-surgery analgaesic. Ketamine (Troy Laboratories Pty Ltd, Australia), MK-801 and d-amphetamine Gamma oscillations and prepulse inhibition 1673 (Sigma-Aldrich, Australia) and LY379268 (Abcam Biochemicals, Sapphire Biosciences Pty Ltd, Australia) were used as the test drugs in the study. Drugs were dissolved in 0.9% saline prior to each session. To dissolve MK-801 and LY379268, solutions were sonicated until clear.
Statistical analysis
The behavioural data and evoked gamma responses were analysed using one-way analysis of variance (ANOVA) with repeated measures (drug), comparing all drug conditions to control (saline). Ongoing gamma power was normalized to the pre-injection period for each trial, and compared between drug treatments over time using two-way ANOVA with repeated measures. Correlational analyses between PPI and either ongoing or stimulustriggered gamma power incorporated values at each 5 min time-point in each drug condition and were done using Pearson's correlation. All statistical comparisons were performed using GraphPad Prism ® , and statistical significance was set at p < 0.05 for all tests. Data are presented as mean±standard error of the mean (S.E.M.). A number of animals were removed over the course of the study due to headpieces dislodging. Our final analysis includes animals (n = 6) that completed all treatments, allowing for repeated measures analyses to be conducted.
Results
Psychotomimetic drugs disrupt prepulse inhibition of the acoustic startle response
As anticipated, we observed significant overall differences in the regulation of PPI between the different drugs measured over the entire session (F (1,5) = 12.9, p < 0.001; Fig. 1a) . Post-hoc analysis revealed that ketamine (50% reduction, p < 0.05), MK-801 (>100% reduction, p < 0.001) and amphetamine (47% reduction, p < 0.05) all significantly disrupted PPI compared to vehicle treatment, but that LY379268 was without effect. We also observed differences in the mean behavioural startle response to the pulse-alone trials between treatments (F (1,5) = 7.5, p < 0.001; Fig. 1b ). Amphetamine (22% increase, p < 0.01) and LY379268 (29% increase, p < 0.001) both increased the startle response compared to vehicle, but treatment with either of the NMDAr antagonists did not influence this measure.
Differential drug effects on EEG spectra and ongoing gamma power
All test drugs substantially impacted frequency spectra over the duration of the experiments (see Fig. 2a ). Overall analysis of ongoing gamma frequency oscillations revealed a significant effect of drug treatment (F (1,5) = 60.9, p < 0.001; Fig. 2b ). As previously reported, both ketamine (p < 0.001) and MK-801 (p < 0.001) increased ongoing gamma power when compared to vehicle treatment, but with different temporal profiles: the effect of ketamine was immediate, peaking 20 min after injection, and then Gamma oscillations and prepulse inhibition 1675 returning to baseline over the time of recording, whereas the effect of MK-801, which peaked around 30 min after injection, was sustained for the duration of the study. Amphetamine also slightly, but significantly, increased gamma power (p = 0.021), an effect that became clear about 40 min after injection. LY379268 was the only compound to significantly reduce gamma power (p < 0.001), achieving a steady reduction to about 55% of baseline levels.
Psychotomimetics disrupt PPI and increase ongoing gamma power in a temporally related fashion
To investigate whether changes in ongoing gamma power were directly related to impaired PPI, we compared the time courses of effects of these two variables for the different drugs (Fig. 3) . Both NMDAr antagonists induced temporally matched disruptions in PPI and elevations in ongoing gamma power (Fig. 3b, c) . Amphetamine also caused a concurrent increase in gamma power and disruption of PPI (Fig. 3d ), but the magnitude of its effect on PPI appeared much greater than its effect on cortical gamma oscillations. In contrast to the other drugs, there was no relationship between the effects of LY379268 on gamma power and sensorimotor gating (Fig. 3e) , perhaps because of the inconsistent effect on PPI of this drug. Linear regression analysis (Fig. 3f) showed that the effects of ketamine (p < 0.001), MK-801 (p < 0.001), and amphetamine (p = 0.02) on behaviour and ongoing gamma power were significantly anti-correlated.
Psychotomimetic drugs reduce sensory-evoked responses and this temporally coincides with impaired PPI Figure 4a illustrates the average event-related spectral perturbation (ERSP) triggered in the ECoG waveform during the PPI trials in the different conditions and Fig. 4b shows the associated ERSP without baseline correction, highlighting the frequency-specific changes caused by each drug. Following a baseline correction, when comparing each drug condition (Fig. 4c) , we observed striking differences in the gamma response immediately following the prepulse, which appears dampened following psychotomimetic administration. When quantifying the power of the sensory-evoked gamma frequency responses occurring within 60 ms following onset of the prepulse, we found significant differences between treatments in stimulus-elicited gamma power, when averaged over the entire recording session (60 epoch averages; F (1,5) = 28.6; p < 0.0001; Fig. 5a ). The three psychotomimetic drugs, ketamine, MK-801 and amphetamine, all significantly reduced the gamma ERSP response to the prepulse compared to saline. LY379268 on the other hand, did not have any effect on the sensory-evoked response. These data associated well with the effects of these drugs on prepulse inhibition (see Fig. 1 ), suggesting a relationship between this electrophysiological measure and behaviour. We also measured the gamma response triggered by the pulse which followed the prepulse. The effects of drug were somewhat similar, although much less dramatic, to those elicited by the prepulse (overall ANOVA: F (1,5) = 9.661; p < 0.0001; Fig. 5b) . When examining the response to trials that were without a prepulse -i.e. pulse alone -the same pattern of EEG responses were observed, with significant reductions in the MK-801 condition (overall ANOVA: F (1,5) = 11.37; p < 0.0001; Fig. 5c ). Because of the potential for movement artefacts to compromise the electrophysiological recordings immediately following the The gamma ERSP response to pulses which followed a prepulse was reduced by MK-801, but no other treatment significantly altered this response. (c) When assessing the gamma ERSP response evoked by the pulses which were not coupled to a prepulse, MK-801 was the only compound to significantly reduce the response. Data represent mean + S.E.M.; n = 6 for all groups. *p < 0.05, ***p < 0.001, ****p < 0.0001 compared to vehicle control.
startling pulse, all other electrophysiological data reported refer to responses evoked by the prepulse. Analysis of the time courses of the effects of the drugs on PPI and on prepulse-evoked gamma responses (Fig. 6) showed that, for the three psychotomimetic drugs, temporal changes in these two measures matched well, with significant correlations being observed (ketamine: r 2 = 0.36, p = 0.03; MK-801: r 2 = 0.70, p < 0.001; amphetamine: r 2 = 0.37, p = 0.03; Fig. 6f ). No such relationship was observed following LY379268 or vehicle treatment.
NMDAr antagonists simultaneously increase ongoing gamma power and reduce sensory-evoked gamma power responses Analysis of the relationship between ongoing and evoked gamma power over the course of the experiment showed that, in the presence of NMDAr antagonists, the reductions in evoked responses were temporally related to the increase in ongoing gamma power (Fig. 7) . Correlational analysis demonstrated that this was highly significant for both ketamine (r 2 = 0.52, p = 0.006) and MK-801 (r 2 = 0.80, p < 0.001), but no relationship for the other treatment conditions existed.
Discussion
Several reports document abnormal regulation of gamma frequency oscillations in schizophrenia (reviewed in Uhlhaas and Singer, 2010) , but whether these are causal to the disease, consequential to the psychotic illness, or unrelated epiphenomena has been difficult to establish. Using a series of drugs with different pharmacological substrates and electrophysiological effects, here we investigated the relationship between evoked and ongoing gamma oscillations and PPI deficits, prominent behavioural features of psychiatric conditions, in particular of schizophrenia (Braff and Geyer, 1990) . We found that treatment with the psychotomimetic compounds MK-801, ketamine and amphetamine all increased ongoing gamma oscillations and reduced sensory-evoked gamma responses, and that these effects were temporally related with behavioural disruptions in prepulse inhibition, used as a measure of sensorimotor gating. LY379268, a preclinical antipsychotic (Cartmell et al., 2000) , reduced ongoing gamma oscillations but did not influence PPI. This work complements previous studies examining electrophysiological activity during a PPI task in healthy humans and patients (Ford et al., 1999 ; Gamma oscillations and prepulse inhibition 1677 Kedzior et al., 2007) , and others which compare and contrast PPI with N40 and P50 gating (Oranje et al., 2006; Swerdlow et al., 2006 Swerdlow et al., , 2012 Holstein et al., 2013) , electrophysiological phenomena used to investigate sensory gating mechanisms. Our study demonstrates strong associations between abnormalities in gamma power and deficits in sensorimotor gating induced by psychotomimetics, and supports the notion that gamma power abnormalities may be relevant to sensory processing disturbances observed in psychiatric disorders particularly those associated with glutamatergic deficiency such as schizophrenia. We, and others, have previously reported that NMDAr antagonists elevate the power of ongoing gamma frequency oscillations (Pinault, 2008; Ehrlichman et al., 2009; Hakami et al., 2009; Jones et al., 2012; Kocsis, 2012; Kulikova et al., 2012) , and proposed that this may represent an electrophysiological correlate of a psychotic-like state. To investigate the functional consequences of alterations in ongoing gamma power, we pharmacologically manipulated this electrophysiological outcome and examined the consequences of this on sensorimotor gating. We found a strong relationship between elevations in ongoing gamma power and disruptions in PPI caused by the NMDAr antagonists, ketamine and MK-801. However, reducing ongoing gamma power with LY379268 did not achieve the heightened PPI levels, which would have been expected if a direct and independent relationship between these outcomes existed. Instead, it appears from our data that there is a relationship between ongoing gamma power and PPI regulation in the context of NMDAr hypofunction. While we also observed such a relationship following amphetamine, this drug induced marked effects on PPI but only caused a small, albeit significant, elevation in ongoing gamma power, making this harder to interpret. Only limited studies have examined ongoing gamma power in schizophrenia, and none have attempted to correlate behavioural endophentoypes to this outcome. However, our evidence suggests a relationship between ongoing gamma power and PPI regulation in pathological conditions particularly associated with NMDA hypofunction, and this should be interrogated in the clinical situation.
While the majority of studies examining gamma frequency oscillations in schizophrenia have grouped patients together regardless of the specific symptom profile or severity of the symptoms, some have attempted to strengthen the association by correlating specific behavioural features with neurophysiological abnormalities (Lee et al., 2003a) . For example, phase locking to a 40-Hz auditory stimulation train is reduced in firstepisode patients with schizophrenia, and this correlates with total positive symptoms in these patients (Spencer et al., 2008) . Also, when performing an auditory oddball task, different schizophrenia syndromes (i.e. psychomotor poverty, reality distortion and disorganization) were differentiated by contrasting patterns of gamma synchrony (Lee et al., 2003b ). Here we show that gamma responses evoked by the prepulse are impaired in rats treated with psychotomimetic compounds, and that these reductions correlate with the disruptions in PPI. Sensoryrelated gamma oscillations appear to be important for the early stages of perception (Haenschel et al., 2000; Kopell et al., 2000) , so reducing the intensity of the signal evoked by the prepulse would be expected to impact the resultant behavioural response. This finding directly links changes in evoked electrophysiological responses with behavioural dysfunction. The relationship was most prominently observed in the NMDAr antagonist conditions, supporting the notion that NMDAr hypofunctionmediated impairment of PPI is related to its effects on gamma frequency oscillations. We also made measurement of the evoked gamma responses, which immediately followed the startling pulse. While these responses were reduced following NMDAr antagonism, just as the response to the prepulse was, these data should be interpreted with caution. Following the presentation of the startling pulse, there is a significant amount of movement -the behavioural startle response -that could create electrophysiological artefacts and potentially interfere with any measure of evoked power made at this time. This limitation does not exist for measurement of the gamma power response evoked by the prepulse, since this does not, in itself, cause any behavioural response.
Instead of focussing on a particular brain region or specific neuronal circuit, we chose to measure cortical EEG during the PPI sessions. The regulation of PPI involves a complex neural circuitry (Swerdlow et al., 2001 ) and measurement of local field potentials in any number of relevant brain regions, such as the supramammillo-septal-hippocampal pathway (Ma and Leung, 2007) , may provide further insight into the electrophysiological regulation of this behaviour. We chose to assess cortical activity because of the ability of this structure to generate gamma oscillations during cognitive processes (Joliot et al., 1994) , and literature is suggestive of functional dysconnectivity in schizophrenia within the cortex (e.g., Friston, 2002; Lewis et al., 2005; Liu et al., 2008) .
Abnormalities in dopaminergic neurotransmission have long been associated with the pathophysiology of schizophrenia (Howes and Kapur, 2009 ). Here we show that amphetamine treatment, which releases dopamine from presynaptic terminals, elevated ongoing gamma power and reduced sensory-evoked responses, suggesting that dopaminergic activation can influence these rhythms. This is in contrast with previous studies, which have suggested that dopaminergic stimulation does not impact either ongoing or sensory-evoked cortical responses (Ehrlichman et al., 2009) , although dopamine antagonism with haloperidol can reduce ongoing gamma activity (Ehrlichman et al., 2009; Jones et al., 2012) . It is not clear why such discrepancies are observed, but it should be noted that the effects of amphetamine in this study on ongoing activity were modest (see also Pinault, 2008) .
In summary, we demonstrated a close temporal relationship between abnormalities in both ongoing and evoked gamma oscillatory power and disruption of PPI following psychotomimetic drug administration. The data from this study significantly strengthen the evidence of a mechanistic link between NMDAr hypofunction, gamma frequency abnormalities and behavioural disturbances, which may have relevance for the pathophysiology of schizophrenia. Future studies should investigate these relationships more closely in patients, and focus on development of therapies, which can alleviate the electrophysiological dysfunction caused by NMDAr hypofunction.
